Safety study of SYHX1903 for blood cancer patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase trial tests whether SYHX1903 is safe and tolerable in people whose blood cancers have come back or did not respond. It may help by finding a workable dose and early safety signals for patients who have limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer diagnosis that has come back or is not responding (relapsed/refractory), confirmed by WHO criteria
- Your daily-function score (ECOG) is 0 or 1
- You have an expected lifespan of at least 3 months
- You are not pregnant and not breastfeeding
- Your cancer is not mainly in the brain/spinal cord (central nervous system)
- You do not have acute promyelocytic leukemia (a specific blood cancer type)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called FXS0683 to treat certain blood cancers (like lymphomas and leukemias) that haven't responded to standard treatments. Researchers want to find the right dose and see if it helps patients whose cancer has come back or isn't responding to other options.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.